<DOC>
	<DOCNO>NCT00615199</DOCNO>
	<brief_summary>This study investigate safety efficacy CP-690,550 adult patient moderate severe Crohn 's disease . The study hypothesis least one dose level test effective placebo ( inactive drug ) .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy CP-690,550 Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects must least 18 year age screening Males females clinical evidence Crohn 's disease least 3 month duration screen Subjects moderate severe Crohn 's Disease baseline , define Crohn 's Disease Activity Index ( CDAI ) score 220450 inclusive Subjects currently receive immunosuppressant , interferon , antiTNFa Subjects evidence hematopoietic disorder Subjects evidence active latent TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>